Boron neutron capture therapy promises targeted tumor destruction through the nuclear reaction of boron-10 with thermal neutrons, but why some tumors respond better than others remains unclear. In the archive, this work sits among studies on radiation therapy, medical imaging, and treatment planning: neighboring preprints address boron measurement in tumors, nitrogen-enhanced proton therapy, noise reduction in X-ray images, and automated radiation therapy planning. This article stands somewhat apart because it focuses not on tools or dosimetry but on comparing the cellular responses of two specific cancer lines under the same irradiation regimen.
Neutrons were produced at a Tandetron accelerator by bombarding a lithium target with 4.5 MeV protons at a current of 10 µA; after moderation in polyethylene, the thermal neutron flux at the cell position was 3.83×10⁷ neutrons per square centimeter per second. SAS and MCF-7 cells were incubated with boronophenylalanine at a concentration of 500 µg/mL for 24 hours, then irradiated for 1, 2, or 3 hours. DNA damage was assessed by gamma-H2AX foci via immunofluorescence, apoptosis and cell cycle were analyzed by flow cytometry with annexin V and propidium iodide staining, and survival was measured by colony formation assay.
After irradiation, SAS cells showed about 70 gamma-H2AX foci per nucleus, while MCF-7 cells showed about 38, whereas without boron these numbers were 18 and 14, respectively. By 24 hours, foci had almost disappeared in both lines. The cell cycle diverged dramatically: in SAS, the proportion of cells in G2/M rose from 28% to 62% by 24 hours, while in MCF-7, the G0/G1 fraction jumped from 33% to 80% as early as 12 hours. Apoptosis in SAS increased from 7.3% to 21.4% over 72 hours, and in MCF-7 from 6.7% to 28.1%, but in the latter, almost all cell death was early apoptosis. Clonogenic survival after 1 hour of irradiation was 15.2% for SAS versus 47.3% for MCF-7; after 3 hours the gap persisted: 10.1% versus 45.1%.
This work shows that sensitivity to boron neutron capture therapy is not simply a matter of how much boron is accumulated: SAS took up about three times more boron than MCF-7, but the differences in cellular response go beyond a simple dose effect. Unlike neighboring studies that focus on improving boron delivery or treatment planning, this is the first to directly compare two cell lines with different p53 status and different cell cycle checkpoint profiles on the same accelerator facility. This underscores the need to consider the molecular portrait of the tumor when predicting therapy efficacy, not just the physical dose.
The topic could evolve toward testing the molecular pathways behind the different cell cycle arrests: ATM/Chk2 for G2/M in SAS and p53/p21 for G0/G1 in MCF-7. It would also be promising to investigate how subcellular boron distribution affects the formation of complex DNA damage, and to test the same patterns in other lines with known p53 status. A separate question is why survival curves plateau after 2 hours of irradiation even though the dose continues to increase.
The results are important for radiation oncology, especially in planning boron neutron capture therapy for head and neck tumors and recurrent breast cancer after photon therapy.
The next step should be to quantitatively assess the activity of checkpoint proteins (ATM, Chk1/2, p53, p21) under the same conditions and to test whether the response changes upon inhibition of specific kinases.
This work directly addresses an unresolved problem in radiobiology: why tumors receiving the same physical radiation dose respond differently. Comparing two lines with different p53 status provides an experimental handle for separating the contributions of boron uptake and intrinsic cellular radiosensitivity, but the molecular mechanism remains a hypothesis that needs testing.
This section is addressed to the author of the paper and their colleagues. Neighbouring works were found by meaning-based search across our archive, not by word overlap. We do not review: we show the field around the work.
What the work does
The study compares how SAS and MCF-7 cell lines respond to boron neutron capture therapy at an accelerator-based source. DNA damage, cell cycle progression, apoptosis, and clonogenic survival were assessed. SAS cells were shown to accumulate more boron, arrest in G2/M, and lose clonogenicity, whereas MCF-7 cells get stuck in G0/G1 and enter apoptosis more slowly.
Where its strength is
The strength of the work lies in the direct comparison of two cell lines with different molecular backgrounds on the same facility, which reveals the role of the cells' own biological features in the response to therapy, not just boron accumulation.
Where it could go next
Worth trying
Why this may matter
Understanding which biological features determine a tumor's response to boron neutron capture therapy could help in patient selection and treatment personalization.
Nearby works in our archive
The archive is sparse around this work: the closest review is only 0.50, against a usual 0.64. It looks like few have drilled nearby.
SAS cells accumulated about three times more boron than MCF-7 (153 µg/L versus 50 µg/L), yet MCF-7 showed higher overall apoptosis by 72 hours, although their colony survival dropped less. This resembles a situation where a louder damage signal does not always mean more reliable cell death.